Erratum
In the original publication of this article [1], the funding section omitted the following information: This work was funded by Momento Medico srl, which has also contributed to the costs for the literature selection and editorial assistance.
References
Blasi F, et al. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients? Respir Res. 2017;18:19. doi:10.1186/s12931-017-0506-0.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1186/s12931-017-0506-0.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Blasi, F., Canonica, G.W. & Miravitlles, M. Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?. Respir Res 18, 35 (2017). https://doi.org/10.1186/s12931-017-0516-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12931-017-0516-y